Sign in →

Epic Code LAB1230353 Dara Antigen

Important Note

Specimens for Blood Bank must have 2 signatures on the specimen written in ink that is resistant to smearing. See Collection Information for more info.

Test Name Alias

Antigen Type | daratumumab | DARAAG | Darzalex | Dara-T

Interface Order Alias

1230353

Icons & Photos

6 mL Pink Top (EDTA) 3 mL Lavender Top (EDTA)

Collection Instructions

Specimen Collection: Blood

 

Container(s): 6 mL Pink Top (EDTA) or 3 mL Lavender Top (EDTA)

Preferred Volume to Collect: 6.0 mL

Minimum Volume to Collect: 1.0 mL

Neonate Volume to Collect: 0.5 mL

Capillary collect ok? Yes

 

Collection Instructions:

  • Gently invert EDTA tube(s) 8 - 10 times after collection.
  • Specimens for Blood Bank must have 2 signatures on the specimen written in ink that is resistant to smearing:
    • User ID's or initials of collectors/witnesses
    • Outpatient collection: The patient may serve as witness and initial the tube label.
    • Policytech reference #6476
  • Specimen must be labeled in the presence of the patient with:
    • Patient's first and last name
    • Unique identification number (MRN)
    • Date of collection
  • If there is any question as to the validity of the specimen identification or an inconsistency between current and previous results, a new specimen must be collected.

Processing Instructions (Laboratory, Outpatient or Off-site collection)

Processed Specimen: Whole Blood EDTA

Centrifuge/Spin: No

Aliquot: No

Transport Temperature: Ambient or Refrigerate

Specimen Stability

Ambient: 24 hours

Refrigerate: 10 days

Laboratory Retention: 10 days

Test Frequency

Available daily, 8AM-3PM, usual TAT 1 day.

Reference Range

Reference range is not available.

Performing Department

BLOOD BANK

Performing Department Laboratory Location

Spectrum Health Butterworth Laboratory. Grand Rapids, MI

Methodology

Currently Unavailable

CPT

86905 x12

CDM Code

80102371 x12

Epic Test ID

1230101937

LOINC

Currently Unavailable

Reviewed Date

9/21/2021 (currently under review)